Business
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
RADNOR, Pa., April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"RADNOR, Pa., April 6, 2021 /PRNewswire/ -- NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries. Aviptadil is being developed by NeuroRx as ZYESAMI™ in collaboration with Relief Therapeutics Holding, AG (SIX: RLF, OTCQB: RLFTF). The trial, designated as TESICO (Therapeutics for Severely Ill Inpatients with COVID-19), is funded by the US Government COVID-19 Therapeutics Response and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The TESICO protocol has been reviewed and approved as a phase III trial by the US Food and Drug Administration and will randomly allocate 640 participants to Aviptadil, Remdesivir, the combination of both drugs and placebo. Remdesivir is currently marketed as Veklury© by Gilead Sciences (Nasdaq: GILD). The primary endpoint of the trial will be participant recovery from respiratory failure over 90 days. Additional information will be supplied by the NIH when the trial randomizes its first patients.\n\n \n \n \n \n \n \n\n \nAbout NeuroRx, Inc.NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp (NASDAQ:BRPA) (\"BRPA\"), and intends to apply for listing on the NASDAQ under the proposed symbol \"NRXP\".\nCautionary Note Regarding Forward Looking StatementsStatements contained in this press release that are not historical facts may be forward-l...